Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTC1PS3)

• DTT Name: Ovarian carcinoma antigen CA125 (MUC16) DTT Info
• Gene Name: MUC16

Molecule-Related Drug & Molecule List

7 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Oregovomab	DM06KRC	Ovarian cancer	2C73	Phase 3	[1]
Abagovomab	DMZ0T24	Ovarian cancer	2C73	Phase 2/3	[2]
REGN4018	DM7LOSK	Ovarian cancer	2C73	Phase 1/2	[3]
REGN5668	DMH1UV5	Ovarian cancer	2C73	Phase 1/2	[4]
DMUC-5754A	DMCT4BA	Fallopian tube cancer	2C74	Phase 1	[5]
JCAR020	DM1T8KN	Ovarian cancer	2C73	Phase 1	[6]
PRGN-3005	DMCUE71	Refractory hematologic malignancy	2A85.5	Phase 1	[7]

1 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
RG7458	DMW87YE	Ovarian cancer	2C73	Discontinued in Phase 1	[8]

References

• [1] MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress. Mol Cancer. 2014; 13: 129.
• [2] Abagovomab: an anti-idiotypic CA-125 targeted immunotherapeutic agent for ovarian cancer. Immunotherapy. 2011 Feb;3(2):153-62.
• [3] A Mucin 16 bispecific T cell-engaging antibody for the treatment of ovarian cancer. Sci Transl Med. 2019 Jun 19;11(497):eaau7534.
• [4] ClinicalTrials.gov (NCT04590326) Phase 1/2 Study of REGN5668 (MUC16xCD28, a Costimulatory Bispecific) Administered in Combination With Cemiplimab or REGN4018 (MUC16xCD3). U.S.National Institutes of Health.
• [5] Maturing antibody-drug conjugate pipeline hits 30. Nat Rev Drug Discov. 2013 May;12(5):329-32.
• [6] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [7] Clinical pipeline report, company report or official report of Precigen.
• [8] Phase I clinical trail of RG7458 for treating Ovarian cancer. Genentech Inc.